[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025

February 2021 | 238 pages | ID: WC570CA1AFAEN
MarketsandMarkets

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period. In the past decade, the demand for various health diagnostic tests has increased significantly across the globe. Currently, the market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe. The increasing adoption of POC diagnostic testing and the growth in the number of diagnostic and imaging centers are also expected to support the growth of this market during the forecast period. However, the high cost of diagnostic devices, tests, and procedures; shortage of skilled laboratory technicians; and insufficient reimbursements for diagnostic tests are expected to restrain this market's growth to a certain extent.

Based on application, the breast cancer testing segment holds the largest market share during the forecast period.

Based on application, the women’s health diagnostics market is divided into nine segments—osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy & fertility testing, prenatal genetic screening & carrier testing, infectious disease testing, STD testing, and ultrasound tests. The breast cancer testing segment accounted for the larger market share in 2019. The large share of this segment can be attributed to the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques, such as ABUS.

Based on end user, the home care settings segment is expected to register the highest CAGR during the forecast period.

Based on end users, the women’s health diagnostics market is segmented into hospitals & clinics, diagnostic & imaging centers, and home care settings. The home care settings segment is expected to witness the highest growth during the forecast period. The increasing advantages of using self-testing kits will continue to drive market growth. Patient self-testing enables patients to better manage their diseases by utilizing home/self-testing kits. Technological advancements have made many self-testing kits available for various conditions, such as pregnancy and ovulation.

North America is expected to account for the largest share of the women’s health diagnostics market in 2019

In 2019, North America accounted for the largest share of the women’s health diagnostics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the increasing prevalence of cancer among women, the growing focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and the increasing demand for fertility testing monitors. In addition, the rising acceptance of POC diagnostics and PST practices is also expected to drive the growth of this regional segment during the forecast period.

Break of primary participants was as mentioned below:
  • By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
  • By Designation – C-level–35%, Director-level–25%, Others–40%
  • By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%
Key players in the Inspection Machines market

The key players operating in the women’s health diagnostics market include Quest Diagnostics Incorporated (US), Hologic, Inc. (US), Siemens AG (Germany), PerkinElmer, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), General Electric Company (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), bioM?rieux SA (France), Koninklijke Philips N.V. (Netherlands), Guided Therapeutics, Inc. (US), SuperSonic Imagine (France), FUJIFILM Holdings Corporation (Japan), DIALAB GmbH (Austria), Carestream Health, Inc. (US), MedGyn Products, Inc. (US), Cook Medical, Inc. (US), Osteometer MediTech, Inc. (Denmark), and NeuroLogica Corporation (US).

Research Coverage:

The report analyzes the women’s health diagnostics market and aims at estimating the market size and future growth potential of this market based on various segments such as application type, end user, and region. The report also includes a product portfolio matrix of various women’s health diagnostic products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global women’s health diagnostics market. The report analyzes this market by application, and end user
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global women’s health diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging markets by application, and end user
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global women’s health diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global women’s health diagnostics market.
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION & SCOPE
  1.2.1 INCLUSIONS AND EXCLUSIONS
  1.2.2 MARKETS COVERED
FIGURE 1 WOMEN’S HEALTH DIAGNOSTICS MARKET
  1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
  2.1.1 SECONDARY RESEARCH
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY RESEARCH
FIGURE 3 PRIMARY SOURCES
    2.1.2.1 Key data from primary sources
    2.1.2.2 Breakdown of primaries
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 7 MARKET ANALYSIS APPROACH
FIGURE 8 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION APPROACH
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

FIGURE 10 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2020 VS. 2025
FIGURE 11 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2020 VS. 2025
FIGURE 12 GEOGRAPHIC SNAPSHOT: WOMEN’S HEALTH DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

4.1 WOMEN’S HEALTH DIAGNOSTICS MARKET OVERVIEW
FIGURE 13 RISING INCIDENCE OF CHRONIC AND LIFESTYLE-RELATED DISORDERS TO DRIVE GROWTH IN THE WOMEN’S HEALTH DIAGNOSTICS MARKET
4.2 APAC: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE (2019)
FIGURE 14 PREGNANCY TESTING & OVULATION PREDICTION KITS DOMINATED THE APAC PREGNANCY & FERTILITY TESTING MARKET IN 2019
4.3 GEOGRAPHIC SNAPSHOT OF THE WOMEN’S HEALTH DIAGNOSTICS MARKET
FIGURE 15 THE US COMMANDED THE LARGEST SHARE OF THE WOMEN’S HEALTH DIAGNOSTICS MARKET IN 2019
4.4 GEOGRAPHIC MIX: WOMEN’S HEALTH DIAGNOSTICS MARKET
FIGURE 16 APAC TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
TABLE 1 WOMEN’S HEALTH DIAGNOSTICS MARKET: IMPACT ANALYSIS
  5.2.1 MARKET DRIVERS
    5.2.1.1 High prevalence of infectious diseases in women
    5.2.1.2 Rising incidence of chronic and lifestyle-related disorders in women
    5.2.1.3 Increasing awareness about fertility testing in women and initiatives by government and health organizations
    5.2.1.4 Increased adoption of POC and rapid diagnostic tests
    5.2.1.5 Growth in the number of private diagnostic and imaging centers
    5.2.1.6 Public-private partnerships are expected to enhance infrastructure in diagnostic imaging centers
  5.2.2 MARKET RESTRAINTS
    5.2.2.1 High cost of diagnostic imaging systems and procedures
    5.2.2.2 Shortage of skilled laboratory technicians
  5.2.3 MARKET OPPORTUNITIES
    5.2.3.1 Improving healthcare infrastructure in emerging markets
    5.2.3.2 Growing number of regulatory approvals for immunoassay diagnostic techniques
  5.2.4 MARKET CHALLENGES
    5.2.4.1 Stringent regulatory guidelines
    5.2.4.2 Increasing adoption of refurbished diagnostic imaging systems
5.3 COVID-19 IMPACT ON THE WOMEN’S HEALTH DIAGNOSTICS MARKET

6 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION

6.1 INTRODUCTION
TABLE 2 WOMEN’S HEALTH DIAGNOSTICS MARKET: PRODUCT PORTFOLIO ANALYSIS
TABLE 3 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.2 BREAST CANCER TESTING
TABLE 4 BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 5 BREAST CANCER TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.1 MAMMOGRAPHY
    6.2.1.1 Rising awareness of early detection of breast cancer to fuel the market growth
TABLE 6 MAMMOGRAPHY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.2 BREAST CANCER TUMOR MARKER TESTS
    6.2.2.1 Increasing number of newly diagnosed breast cancer cases will drive the demand for breast cancer tumor marker tests
TABLE 7 BREAST CANCER TUMOR MARKER TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.3 BLOOD CHEMISTRY & BLOOD CELL COUNT TESTS
    6.2.3.1 Growing need for checking the proper functioning of body organs and preventing the spread of infection to other organs will drive market growth
TABLE 8 BLOOD CHEMISTRY & BLOOD CELL COUNT TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.4 BIOPSIES
    6.2.4.1 Growing incidence of breast cancer and high demand for minimally invasive procedures to augment market growth
TABLE 9 BIOPSIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.5 OTHER BREAST CANCER TESTS
TABLE 10 OTHER BREAST CANCER TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.3 INFECTIOUS DISEASE TESTING
TABLE 11 INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 12 INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.3.1 UTI TESTING
    6.3.1.1 Technological advancements like CT scans and ultrasound increase the need for UTI testing
TABLE 13 UTI TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.3.2 HEPATITIS TESTING
    6.3.2.1 Dynamic shift from traditional diagnostic procedures to portable tests is expected to propel market growth
TABLE 14 HEPATITIS TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.3.3 TUBERCULOSIS TESTING
    6.3.3.1 Rising tuberculosis cases in women will drive the demand for infectious disease testing
TABLE 15 TUBERCULOSIS TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.3.4 MRSA TESTING
    6.3.4.1 Development of rapid MRSA tests will drive the market growth
TABLE 16 MRSA TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.3.5 OTHER INFECTIOUS DISEASE TESTS
TABLE 17 OTHER INFECTIOUS DISEASE TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.4 CERVICAL CANCER TESTING
TABLE 18 CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 19 CERVICAL CANCER TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.4.1 HPV TESTING
    6.4.1.1 Easy availability of advanced tests and growing demand for using Pap/HPV co-testing to support market growth
TABLE 20 HPV TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.4.2 PAP SMEARS
    6.4.2.1 Rising cervical cancer cases and government initiatives are propelling the growth of the market
TABLE 21 PAP SMEARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.5 STD TESTING
TABLE 22 STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 23 STD TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.5.1 HIV TESTING
    6.5.1.1 Increasing government support and technological advancements are major factors driving market growth
TABLE 24 HIV TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.5.2 CT/NG TESTING
    6.5.2.1 Technological advancements and rapid testing to drive market growth in this application segment
TABLE 25 CT/NG TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.5.3 OTHER STD TESTS
TABLE 26 OTHER STD TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.6 OSTEOPOROSIS TESTING
TABLE 27 OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 28 OSTEOPOROSIS TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.6.1 IN VITRO BLOOD TESTS
    6.6.1.1 Growing risk of osteoporosis in women during menopause to drive the demand for in vitro blood tests
TABLE 29 IN VITRO BLOOD TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.6.2 BONE DENSITOMETRY
    6.6.2.1 Growing aging population and high prevalence of osteoporosis in woman to drive the demand for this application segment
TABLE 30 BONE DENSITOMETRY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.7 PRENATAL GENETIC SCREENING & CARRIER TESTING
TABLE 31 PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 32 PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.7.1 DOWN’S SYNDROME AND EDWARDS’ SYNDROME TESTING
    6.7.1.1 Rising need for prenatal screening and easy availability of these tests to support market demand
TABLE 33 DOWN’S SYNDROME AND EDWARDS’ SYNDROME TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.7.2 TORCH TESTING
    6.7.2.1 Various advantages of TORCH testing to drive the market demand
TABLE 34 TORCH TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.7.3 CF TESTING
    6.7.3.1 Growing awareness about genetic disorders like cystic fibrosis to increase the demand for CF testing
TABLE 35 CF TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.7.4 OTHER PRENATAL GENETIC DISEASE TESTS
TABLE 36 OTHER PRENATAL GENETIC DISEASE TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.8 PREGNANCY & FERTILITY TESTING
TABLE 37 PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 38 PREGNANCY & FERTILITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.8.1 PREGNANCY TESTING & OVULATION PREDICTION KITS
    6.8.1.1 Growing preference for confidentiality and accessibility of test results will drive market demand
TABLE 39 PREGNANCY TESTING & OVULATION PREDICTION KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.8.2 LAB-BASED TESTING
    6.8.2.1 Increasing reliability of lab-based fertility tests to fuel market growth
TABLE 40 LAB-BASED TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.8.3 FERTILITY MONITORS
    6.8.3.1 Fast and accurate data generation to increase the demand for fertility monitors
TABLE 41 FERTILITY MONITORS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.9 ULTRASOUND TESTS
TABLE 42 ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 43 ULTRASOUND TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.9.1 OB/GYN IMAGING
    6.9.1.1 Growing demand for minimally invasive techniques in gynecological applications to support market growth
TABLE 44 OB/GYN IMAGING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.9.2 BREAST IMAGING
    6.9.2.1 Growing cases of breast cancer and the need for non-invasive procedures will drive the market demand for breast imaging
TABLE 45 BREAST IMAGING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.10 OVC TESTING
TABLE 46 OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 47 OVC TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.10.1 OVC TUMOR MARKER TESTS
    6.10.1.1 Need for early diagnosis of OVC will drive the demand for advanced diagnostic devices
TABLE 48 OVC TUMOR MARKER TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.10.2 OVC DIAGNOSTIC IMAGING TESTS
    6.10.2.1 Rising prevalence of women’s health-related disorders and growing awareness about various imaging tests to drive market growth
TABLE 49 OVC DIAGNOSTIC IMAGING TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.10.3 OTHER OVC TESTS
TABLE 50 OTHER OVC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

7 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER

7.1 INTRODUCTION
7.2 COVID-19 IMPACT ON THE WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER
TABLE 51 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
7.3 HOSPITALS & CLINICS
  7.3.1 HOSPITALS & CLINICS ARE EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD
TABLE 52 WOMEN’S HEALTH DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2018–2025 (USD MILLION)
7.4 DIAGNOSTIC & IMAGING CENTERS
  7.4.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO
DRIVE MARKET GROWTH
TABLE 53 WOMEN’S HEALTH DIAGNOSTICS MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY COUNTRY, 2018–2025 (USD MILLION)
7.5 HOME CARE SETTINGS
  7.5.1 INCREASING ADVANTAGES OF USING SELF-TESTING KITS TO DRIVE GROWTH IN THE MARKET
TABLE 54 WOMEN’S HEALTH DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2018–2025 (USD MILLION)

8 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY REGION

8.1 INTRODUCTION
8.2 COVID-19 IMPACT ON VARIOUS REGIONS IN THE WOMEN’S HEALTH DIAGNOSTICS MARKET
FIGURE 17 WOMEN’S HEALTH DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2019)
TABLE 55 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY REGION, 2018–2025 (USD MILLION)
8.3 NORTH AMERICA
FIGURE 18 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET SNAPSHOT
TABLE 56 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 57 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 58 NORTH AMERICA: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 59 NORTH AMERICA: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 60 NORTH AMERICA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 61 NORTH AMERICA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 62 NORTH AMERICA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 63 NORTH AMERICA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 64 NORTH AMERICA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 65 NORTH AMERICA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 66 NORTH AMERICA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 67 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.3.1 US
    8.3.1.1 The US dominates the North American women’s health diagnostics market
TABLE 68 US: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 69 US: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 70 US: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 71 US: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 72 US: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 73 US: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 74 US: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 75 US: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 76 US: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 77 US: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 78 US: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.3.2 CANADA
    8.3.2.1 Surge in chronic lifestyle diseases and infectious diseases to support market growth in Canada
TABLE 79 CANADA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 80 CANADA: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 81 CANADA: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 CANADA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 83 CANADA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 84 CANADA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 85 CANADA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 86 CANADA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 87 CANADA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 88 CANADA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 89 CANADA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
8.4 EUROPE
TABLE 90 EUROPE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 91 EUROPE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 92 EUROPE: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 93 EUROPE: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 94 EUROPE: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 95 EUROPE: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 96 EUROPE: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 97 EUROPE: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 98 EUROPE: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 99 EUROPE: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 100 EUROPE: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 101 EUROPE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.4.1 GERMANY
    8.4.1.1 Growing investments by government and private contributors to fuel market growth
TABLE 102 GERMANY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 103 GERMANY: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 104 GERMANY: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 105 GERMANY: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 106 GERMANY: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 107 GERMANY: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 108 GERMANY: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 109 GERMANY: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 110 GERMANY: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 111 GERMANY: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 112 GERMANY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.4.2 UK
    8.4.2.1 Rising incidence of PCOS to increase the demand for diagnostic tests
TABLE 113 UK: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 114 UK: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 115 UK: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 116 UK: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 117 UK: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 118 UK: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 119 UK: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 120 UK: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 121 UK: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 122 UK: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 123 UK: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.4.3 FRANCE
    8.4.3.1 Growing infertility rate among women in the country and rising cancer cases to drive the market
TABLE 124 FRANCE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 125 FRANCE: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 126 FRANCE: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 127 FRANCE: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 128 FRANCE: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 129 FRANCE: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 130 FRANCE: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 131 FRANCE: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 132 FRANCE: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 133 FRANCE: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 134 FRANCE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.4.4 ITALY
    8.4.4.1 Increasing acceptance of molecular diagnostics-based personalized medicine and rising chronic diseases are major driving factors
TABLE 135 ITALY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 136 ITALY: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 137 ITALY: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 138 ITALY: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 139 ITALY: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 140 ITALY: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 141 ITALY: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 142 ITALY: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 143 ITALY: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 144 ITALY: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 145 ITALY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.4.5 SPAIN
    8.4.5.1 Improving healthcare system and increasing healthcare expenditure in Spain to drive market growth
TABLE 146 SPAIN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 147 SPAIN: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 148 SPAIN: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 149 SPAIN: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 150 SPAIN: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 151 SPAIN: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025, (USD MILLION)
TABLE 152 SPAIN: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 153 SPAIN: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 154 SPAIN: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 155 SPAIN: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 156 SPAIN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.4.6 ROE
TABLE 157 ROE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 158 ROE: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 159 ROE: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 160 ROE: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 161 ROE: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 162 ROE: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 163 ROE: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 164 ROE: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 165 ROE: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 166 ROE: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 167 ROE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
8.5 APAC
FIGURE 19 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET SNAPSHOT
TABLE 168 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 169 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 170 APAC: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 171 APAC: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 172 APAC: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 173 APAC: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 174 APAC: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 175 APAC: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 176 APAC: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 177 APAC: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 178 APAC: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 179 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.5.1 CHINA
    8.5.1.1 Increasing urbanization and growing government initiatives to drive market growth in China
TABLE 180 CHINA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 181 CHINA: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 182 CHINA: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 183 CHINA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 184 CHINA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 185 CHINA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 186 CHINA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 187 CHINA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 188 CHINA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025, (USD MILLION)
TABLE 189 CHINA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 190 CHINA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.5.2 JAPAN
    8.5.2.1 Presence of a universal healthcare reimbursement scenario and well-developed healthcare system to drive market growth in Japan
TABLE 191 JAPAN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 192 JAPAN: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 193 JAPAN: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 194 JAPAN: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 195 JAPAN: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 196 JAPAN: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 197 JAPAN: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 198 JAPAN: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 199 JAPAN: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 200 JAPAN: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 201 JAPAN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.5.3 INDIA
    8.5.3.1 Improving healthcare infrastructure and growing private and public investments to support the market growth
TABLE 202 INDIA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 203 INDIA: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 204 INDIA: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 205 INDIA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 206 INDIA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 207 INDIA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 208 INDIA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 209 INDIA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 210 INDIA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 211 INDIA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 212 INDIA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
  8.5.4 ROAPAC
TABLE 213 ROAPAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 214 ROAPAC: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 215 ROAPAC: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 216 ROAPAC: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 217 ROAPAC: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 218 ROAPAC: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 219 ROAPAC: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 220 ROAPAC: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 221 ROAPAC: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 222 ROAPAC: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 223 ROAPAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
8.6 LATIN AMERICA
  8.6.1 AVAILABILITY OF ADVANCED CARE AND INCREASING AWARENESS PROGRAMS TO FUEL MARKET GROWTH
TABLE 224 LATIN AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 225 LATIN AMERICA: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 226 LATIN AMERICA: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 227 LATIN AMERICA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 228 LATIN AMERICA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 229 LATIN AMERICA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 230 LATIN AMERICA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 231 LATIN AMERICA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 232 LATIN AMERICA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 233 LATIN AMERICA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 234 LATIN AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
8.7 MIDDLE EAST & AFRICA
  8.7.1 INCREASING INCIDENCE OF LIFESTYLE DISEASES TO AUGMENT MARKET GROWTH IN THE MIDDLE EAST & AFRICA
TABLE 235 MIDDLE EAST & AFRICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 236 MIDDLE EAST & AFRICA: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 237 MIDDLE EAST & AFRICA: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 238 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 239 MIDDLE EAST & AFRICA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 240 MIDDLE EAST & AFRICA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 241 MIDDLE EAST & AFRICA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 242 MIDDLE EAST & AFRICA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 243 MIDDLE EAST & AFRICA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 244 MIDDLE EAST & AFRICA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 245 MIDDLE EAST & AFRICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
FIGURE 20 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2018 TO DECEMBER 2020
9.2 GEOGRAPHICAL ASSESSMENT OF THE MAJOR PLAYERS IN THE WOMEN’S HEALTH DIAGNOSTICS MARKET
FIGURE 21 GEOGRAPHIC REVENUE MIX: WOMEN’S HEALTH DIAGNOSTICS MARKET (2019)
9.3 REVENUE SHARE ANALYSIS OF TOP PLAYERS
FIGURE 22 TOP PLAYERS DOMINATE THE GLOBAL MARKET
9.4 MARKET SHARE ANALYSIS
FIGURE 23 WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2019
9.5 COMPETITIVE LEADERSHIP MAPPING
  9.5.1 STARS
  9.5.2 EMERGING LEADERS
  9.5.3 PERVASIVE PLAYERS
  9.5.4 EMERGING COMPANIES
FIGURE 24 WOMEN’S HEALTH DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
9.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
  9.6.1 PROGRESSIVE COMPANIES
  9.6.2 DYNAMIC COMPANIES
  9.6.3 STARTING BLOCKS
  9.6.4 RESPONSIVE COMPANIES
FIGURE 25 WOMEN’S HEALTH DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2019)
9.7 COMPETITIVE SITUATION AND TRENDS
  9.7.1 PRODUCT LAUNCHES & ENHANCEMENTS
  9.7.2 EXPANSIONS
  9.7.3 ACQUISITIONS
  9.7.4 OTHER STRATEGIES

10 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 QUEST DIAGNOSTICS INCORPORATED
FIGURE 26 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2019)
10.2 HOLOGIC, INC.
FIGURE 27 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
10.3 SIEMENS AG
FIGURE 28 SIEMENS AG: COMPANY SNAPSHOT (2020)
10.4 PERKINELMER, INC.
FIGURE 29 PERKINELMER, INC.: COMPANY SNAPSHOT (2019)
10.5 F. HOFFMANN-LA ROCHE LTD.
FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
10.6 CARDINAL HEALTH, INC.
FIGURE 31 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT (2020)
10.7 GENERAL ELECTRIC COMPANY
FIGURE 32 GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT (2019)
10.8 BECTON, DICKINSON AND COMPANY
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
10.9 ABBOTT LABORATORIES
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
10.10 BIOM?RIEUX SA
10.11 KONINKLIJKE PHILIPS N.V.
FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2019)
10.12 GUIDED THERAPEUTICS, INC.
10.13 SUPERSONIC IMAGINE
10.14 FUJIFILM HOLDINGS CORPORATION
10.15 DIALAB GMBH
10.16 CARESTREAM HEALTH, INC.
10.17 MEDGYN PRODUCTS, INC.
10.18 COOK MEDICAL, INC.
10.19 OSTEOMETER MEDITECH, INC.
10.20 NEUROLOGICA CORPORATION
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

11.1 INSIGHTS FROM INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS


More Publications